Literature DB >> 10471129

Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans.

T L Goodfriend1, B M Egan, D E Kelley.   

Abstract

Aldosterone production in vitro can be affected by many hormones, autacoids, ions, and lipids, but regulation in humans is incompletely understood. We measured plasma aldosterone in adult subjects with a wide range of obesity and insulin resistance. Aldosterone levels correlated with measures of visceral obesity in one predominantly male cohort and in the women of a second cohort. In the same subjects, aldosterone correlated with insulin resistance. Aldosterone also correlated with plasma cortisol in men and women, and with DHEA-S in women. The data suggested that visceral fat stimulates adrenal steroidogenesis. We found that certain fatty acids stimulated aldosterone production in vitro by rat adrenal cells incubated with rat hepatocytes, but not adrenal cells alone. The results suggested that fatty acids from visceral adipocytes induce hepatic formation of an adrenal secretagogue. This may explain the correlation of plasma steroids with visceral obesity. Aldosterone may contribute to vascular diseases that complicate obesity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471129     DOI: 10.1016/s0952-3278(99)80020-9

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  30 in total

Review 1.  The adrenal and the metabolic syndrome.

Authors:  M S Golub
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

Review 2.  New developments in mechanisms of obesity-induced hypertension: role of adipose tissue.

Authors:  A M Sharma; S Engeli; T Pischon
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

3.  Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets.

Authors:  J M Luther; P Luo; M T Kreger; M Brissova; C Dai; T T Whitfield; H S Kim; D H Wasserman; A C Powers; N J Brown
Journal:  Diabetologia       Date:  2011-04-26       Impact factor: 10.122

Review 4.  The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: an update.

Authors:  Guido Lastra-Gonzalez; Camila Manrique-Acevedo; James R Sowers
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

5.  Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults.

Authors:  Jennifer N Cooper; Linda Fried; Ping Tepper; Emma Barinas-Mitchell; Molly B Conroy; Rhobert W Evans; Maria Mori Brooks; Genevieve A Woodard; Kim Sutton-Tyrrell
Journal:  Hypertens Res       Date:  2013-05-09       Impact factor: 3.872

6.  Aldosterone, Renin, and Diabetes Mellitus in African Americans: The Jackson Heart Study.

Authors:  Joshua J Joseph; Justin B Echouffo-Tcheugui; Rita R Kalyani; Hsin-Chieh Yeh; Alain G Bertoni; Valery S Effoe; Ramon Casanova; Mario Sims; Adolfo Correa; Wen-Chih Wu; Gary S Wand; Sherita H Golden
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

7.  Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.

Authors:  Tanja Dudenbostel; Lama Ghazi; Mingchun Liu; Peng Li; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-08-15       Impact factor: 10.190

Review 8.  The renin angiotensin aldosterone system and insulin resistance in humans.

Authors:  Patricia C Underwood; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

Review 9.  Aldosterone in vascular and metabolic dysfunction.

Authors:  James M Luther
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-01       Impact factor: 2.894

10.  Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways.

Authors:  H D Long; Y E Lin; M J Liu; L Y Liang; Z H Zeng
Journal:  J Endocrinol Invest       Date:  2013-04-23       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.